Krystal Biotech (KRYS) Operating Leases (2019 - 2026)
Krystal Biotech (KRYS) posted quarterly Operating Leases of $8.9 million for Q2 2026, down 8.55% year-over-year from $9.7 million in Q2 2025, and down 2.84% on a QoQ basis from $9.1 million in Q1 2026.
Krystal Biotech (KRYS) Operating Leases (2019 - 2026) Analysis & Trends
Krystal Biotech has reported Operating Leases for 8 years, with the latest figure at $8.9 million in Q2 2026.
- Operating Leases for Q2 2026 came in at $8.9 million, down 8.55% year-over-year; the trailing twelve-month figure through Jun 2026 was $8.9 million (down 8.55% YoY), and the FY2025 annual result was $7.6 million, up 25.22% from the prior year.
- Operating Leases eased to $8.9 million in Q2 2026, from $9.1 million in the prior quarter.
- Over five years, Operating Leases peaked at $9.7 million in Q2 2025 and troughed at $6.0 million in Q4 2024.
- A 5-year average of $8.5 million and a median of $8.8 million in 2023 frame the typical range for Operating Leases.
- The widest annual swing landed in 2022, when Operating Leases surged 140.16%; it then retreated 25.89% in 2023.
- A 5-year view of Operating Leases shows it stood at $8.9 million in 2022, then dropped by 25.89% to $6.6 million in 2023, then decreased by 8.7% to $6.0 million in 2024, then gained by 25.22% to $7.6 million in 2025, then climbed by 16.98% to $8.9 million in 2026.
- Per Business Quant data, the three most recent Operating Leases figures were $8.9 million in Q2 2026, $9.1 million in Q1 2026, and $7.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.85 Mn |
| Mar 31, 2026 | 7.31 Mn |
| Dec 31, 2025 | 7.57 Mn |
| Sep 30, 2025 | 7.81 Mn |
| Jun 30, 2025 | 9.68 Mn |
| Mar 31, 2025 | 8.30 Mn |
| Dec 31, 2024 | 6.04 Mn |
| Sep 30, 2024 | 6.18 Mn |
| Jun 30, 2024 | 7.69 Mn |
| Mar 31, 2024 | 6.47 Mn |
| Dec 31, 2023 | 6.62 Mn |
| Sep 30, 2023 | 8.32 Mn |
| Jun 30, 2023 | 7.01 Mn |
| Mar 31, 2023 | 7.21 Mn |
| Dec 31, 2022 | 7.37 Mn |
| Sep 30, 2022 | 7.58 Mn |
| Jun 30, 2022 | 9.13 Mn |
| Mar 31, 2022 | 9.29 Mn |
| Dec 31, 2021 | 8.02 Mn |
| Sep 30, 2021 | 8.10 Mn |